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Objective: The objective of this selective EBM review is to determine whether or not 
mindfulness-based cognitive therapy is effective for preventing relapse of depression in adults. 
 
Study Design: Review of three English-language randomized controlled trials published between 
2014 and 2015.  
 
Data Sources: Three randomized controlled trials published in peer-reviewed journals comparing 
mindfulness-based cognitive therapy to comparable treatment options found via PubMed. 
 
Outcomes measured: Outcome measured was presence or absence of relapse of major depressive 
episodes in adults determined by the Structured Clinical Interview for DSM-IV.  
 
Results: Kuyken et al. found that there was not a statistically significant difference in the 
incidence of relapse of depression in a adults between those using MBCT and those on 
maintenance anti-depressant therapy (p=.43 Lancet. 2015;386(9988):63-73. doi: S0140-
6736(14)62222-4 [pii]). After further analysis, the NNT for this study of 33 indicated a small 
treatment effect. Similarly, Shallcross et al. again found no difference between groups receiving 
MBCT and those participating in an active control condition (p=.91 J Consult Clin Psychol. 
2015;83(5):964-975. doi: 10.1037/ccp0000050 [doi].). Again, after analysis there was a small 
treatment effect (NNT=-45). Finally, Williams et al. again showed no significant difference in 
relapse rates between groups receiving MBCT combined with TAU and those using TAU 
alone(p=.13 J Consult Clin Psychol. 2014;82(2):275-286. doi: 10.1037/a0035036). However, 
upon further analysis their treatment effects were found to be the largest of the three studies 
evaluated in this review (NNT=14). 
 
Conclusion: This review showed that there is no difference between MCBT and control 
conditions in successful prevention of depressive episodes in adults. It was determined that 
MBCT is a viable treatment option for those with MDD, but it was not shown to be superior to 
other know treatment modalities such as antidepressant therapy or psychotherapy.   
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INTRODUCTION 
Major depressive disorder (MDD) is a chronic and incapacitating disease affecting 
approximately 6% of adults worldwide each year.1 Additionally, about one in five people will 
meet diagnostic criteria for MDD throughout their lifetime.1 Major depressive disorder is 
characterized by at least one discrete depressive episode lasting two weeks or longer, involving  
some or all of the following signs: clear-cut changes in mood, interests, pleasure, cognition and 
vegetative symptoms.1 The exact pathophysiology of MDD is unknown, but there are many 
hypotheses that genetic and environmental factors, such as disordered reuptake of serotonin and 
adverse childhood events respectively, are involved in the development of this condition.1 It is 
known that the condition affects patients’ quality of life by impairing cognition, disrupting social 
and occupational functioning, and increasing patients’ suicide risk and overall mortality rate.1 In 
addition to affecting patients’ mental health, major depressive disorder has also been associated 
with increased risk of developing other physical illnesses such as diabetes mellitus, heart disease, 
and stroke.1 
According to the National Ambulatory Medical Care Survey performed by the CDC, 
there were approximately 11 million healthcare visits for depressive disorders, excluding bipolar 
depression, in the year 2016 in the United States alone.2 In 2013, $71 billion was spent treating 
depression in the US, 53% of that being in an ambulatory care setting. It was the sixth most 
costly condition to treat overall, and the number one most expensive mental disorder to treat.3 
Typical management of major depressive disorder combines psychotherapy and pharmacologic 
anti-depressant therapy, such as selective serotonin reuptake inhibitors (SSRI) among others.1 
Because MDD is a complex disorder, no single treatment has been found to be a cure-all, and 
relapses are common for patients with this condition.1 This information, combined with the 
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statistics presented above, demonstrates the necessity for healthcare resources to be allocated 
toward treating MDD, and also that new approaches to treatment continue to be developed and 
researched. 
Mindfulness-based cognitive therapy (MBCT) is a manualized, group therapy that 
combines the attentional training of mindfulness meditation with the activation and 
psychoeducation elements of cognitive therapy.4 Mindfulness itself is the process of learning to 
be aware of and wholly present in the moment at hand. It encourages the practitioner to avoid 
judgment of any bodily sensations, thoughts, and surrounding environmental stimuli, in an effort 
to practice being open, accepting, and curious.5 In the setting of MDD, the goal of mindfulness is 
that the patient will learn to recognize a worsening of their mood, without reacting to and 
judging themselves for the change.5 The overarching theoretical premise of mindfulness-based 
interventions is that, by practicing mindfulness, individuals will become less reactive to 
unpleasant internal phenomena, and more reflective, which in turn will lead to positive 
psychological outcomes.5 This paper evaluates three randomized controlled trials (RCTs) 
comparing the efficacy of MBCT as a means to prevent relapse of depression in adults with other 
therapies.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not mindfulness-
based cognitive therapy is effective for preventing relapse of depression in adults. 
METHODS 
 All research was completed by the author of this review using the PubMed database. Key 
words used in searches included “major depressive disorder” and “mindfulness-based cognitive 
therapy.” Articles were selected based on their relevance to the author’s question and if the 
2 
  O’Brien, MBCT and depression,  
outcomes measured were patient-oriented outcomes, or POEMs. All articles were published in 
peer-reviewed journals and written in the English language. Inclusion criteria were studies 
published within the past ten years at the time of the search, and studies structured as a 
randomized controlled trial. Studies were excluded if they were published before the year 2008. 
The statistics reported and used included p-value, confidence interval, experimental group event 
rate (EER), and control group event rate (CER).  
 The population evaluated in the selected studies was adults with a history of at least one 
major depressive episode. The studies selected for this review were three randomized controlled 
trials using mindfulness-based cognitive therapy as the experimental intervention for MDD, with 
comparable control conditions. Those comparison control groups included maintenance anti-
depressant therapy6, active control condition lacking a mindfulness component7, and treatment as 
usual.8 The outcomes measured by all studies were the presence or absence of a relapse of 
depressive episodes, measured by the Structured Clinical Interview for DSM-IV (SCID). Below, 
Table 1 provides a summary of the demographics and descriptions of the studies evaluated in this 
review. 
OUTCOMES MEASURED 
 The outcome measured in this selective EBM review was the presence or absence of 
relapse of major depressive episodes in adults determined by the Structured Clinical Interview 
for DSM-IV (SCID) performed by trained assessors.  
RESULTS 
 In this selective EBM review, three studies comparing mindfulness-based cognitive 
therapy to a comparative treatment option were evaluated in adults who had been previously 
diagnosed with major depressive disorder and achieved remission before the start of the trial.  
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Table 1. Demographics and Descriptions of Included Studies 
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Kuyken et al. recruited participants from primary care practices in the UK who had at 
least three prior episodes of MDD and were currently on therapeutic anti-depressant 
medications.6 Further inclusion and exclusion criteria can be found in Table 1. The study 
randomly assigned 212 patients to the control group continuing on maintenance anti-depressant 
medication, and 212 patients to the experimental group who participated in an eight-week MBCT 
course with support to taper or discontinue their anti-depressant medications during the course of 
treatment.6 The researchers determined the experimental and control groups were of similar 
composition at the start of the trial and did not note any known biases. The participants were 
made aware of their group assignment; however, the raters of this study were blind to the 
assignments. The follow-up of patients was sufficiently long at 24 months after the start of the 
trial. The researchers evaluated patients at six different times throughout the two year period: one 
month after the MBCT course ended (equivalent time for control group), and at 9, 12, 18, and 24 
months.6 At that time 366 of the 424 participants remained in the trial, meaning losses to follow-
up were less than 20%. A worst-case analysis was not performed on the subjects lost to follow-
up, but the remaining patients were analyzed with an intention-to-treat analysis. The study used 
an intention to treat analysis hazard ratio to measure the time to relapse for both the experimental 
and control groups.6 They found that there was no significant difference between the 
experimental and control groups, and that both treatment modalities were similarly effective at 
preventing relapse of depressive episodes. (Hazard ratio 0.89, 95% CI 0.67-1.18, p= 0.43)6 
This review further analyzed the data presented in the study performed by Kuyken et al., 
using the raw data of relapse rates of depression. Success was considered absence of relapse of 
depressive episodes, and failure was considered at least one relapse of depressive episodes over 
the course of the 24-month study. It was reported that 44% of the experimental group (EER) and 
5 
  O’Brien, MBCT and depression,  
47% of the control group (CER) experienced a relapse in depressive episodes. The relative risk 
reduction (RRR), absolute risk reduction (ARR), and numbers needed to treat (NNT) were 
calculated based on the number of patients who relapsed in each group and the data is 
summarized in Table 2 below.  
Table 2. Treatment effects for Kuyken et al.6 
EER CER RRR ARR NNT 
.44 .47 .064 .03 33 
 
Shallcross et al. recruited participants from the urban areas in the Rocky Mountain West 
section of the United States through referrals from mental health centers based in the community 
and advertisements. From over 1000 applicants, 92 participants were selected to be involved in 
the study, with inclusion and exclusion criteria detailed in Table 1. The experimental group 
received an 8-week MBCT course, and the control group participated in what this study 
describes as an active control condition. This included classes involving physical activity and 
movement, music, and nutrition, with no mindfulness components.7 The study made in-class 
time and out-of-class homework equal for both groups.7 There were 46 participants randomly 
allocated to both the experimental and control groups, and they were determined to have similar 
composition. As in the research conducted by Kuyken et al., the participants in the study were 
not blind to their group assignment, but the interviewers conducting SCID to determine relapse 
of depression were masked to the assignments.7 Follow-up was sufficiently long, with patients 
being evaluated over a 60-week time period. This study performed an intention to treat analysis 
with the results yielding hazard ratio=.945, 95% CI .364-2.45, p=.9.  Similar to the study 
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described above, Shallcross et al. did not find a statistically significant difference in relapse rates 
between the MBCT group and the active control group.   
Again, this review further investigated the incidence of relapse of depressive episodes, 
using the same parameters for success and failure as noted above. With 32.6% of the 
experimental group (EER) and 30.4% of the control group (CER) relapsing, the RRR, ARR, and 
NNT were calculated and displayed in Table 3 below.  
Table 3: Treatment effects for Shallcross et al. 
EER CER RRR ARR NNT 
.326 .304 -.007 -.022 -45 
 
Williams et al. conducted a randomized controlled trial with three arms: MBCT with 
treatment as usual, cognitive psychological education with treatment as usual, and treatment as 
usual (TAU) alone as the control group. The researchers conducted separate analyses comparing 
each of the two experimental arms to the control condition, so this review only took into account 
the experimental arm using MBCT and the control group, as they are most similar to the other 
studies considered in this analysis. The study recruited participants though advertisements and 
referrals from primary care and outpatient mental health clinics in the UK.8 A total of 164 
participants comprised the arms evaluated by this review, with 108 participants randomly 
allocated to the MBCT with TAU experimental group and 56 to the TAU control group. More 
comprehensive inclusion/exclusion criteria and intervention description is detailed in Table 1. 
Like the studies previously described, participants were aware of their group assignment, but 
assessors were blind to that information. All participants were encouraged to continue TAU, 
which included their current medication regimen, psychotherapy, or other services used to reach 
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remission prior to the start of the trial, and it was determined “there was no significant 
differences between groups in pharmacological or psychiatric/psychological treatment 
received.”8 Follow up was sufficiently long, as patients were assessed immediately after 
treatment course was completed (equivalent time frame for control group) and then at 3, 6, 9, and 
12 months.8 Losses to follow-up were 7.3%, and there was no mention of a worst-case analysis. 
An intention to treat analysis was performed with a Cox regression for time to relapse yielding 
the following results: hazard ratio= 0.68, 95% CI 0.42-1.12, and p=.13.8 Williams et al. also 
determined there was not a statistically significant difference between the MBCT and control 
groups.  
 As with the other studies, this review analyzed the relapse rates from the experimental 
and control groups, again using the same criteria for success and failure. Of the 108 participants 
in the experimental MBCT group 46% relapsed, while 53% of the TAU control group relapsed. 
RRR, ARR, and NNT were calculated and presented in Table 4 below. Of the three studies 
presented, this analysis shows the study performed by Williams et al. had the largest treatment 
effect with NNT being the lowest of the three.  
Table 3: Treatment effects for Williams et al. 
EER CER RRR ARR NNT 
.46 .53 .13 .07 14 
 
DISCUSSION 
 Major depressive disorder is a complicated condition with many factors contributing to 
its development that can make the presentation, symptoms, and severity of the disease variable 
from patient to patient. For that reason, there are a variety of treatment options available and 
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much of the approach to treatment is trial and error to discover what works for each individual. 
Because the exact pathophysiology is unknown and is most likely a combination of factors rather 
than one etiology, it is common for patients to utilize multiple treatment approaches. MBCT has 
been suggested as a treatment option for depression to help patients be less reactive to negative 
internal thoughts and feelings, in an effort to improve their overall disease course and risk of 
relapse.5 An interesting correlation noted by both Kuyken et al. and Williams et al., was that a 
subgroup in their respective studies who reported a severe history of childhood trauma had a 
drastically lower rate of relapse in the MBCT groups as compared to those allocated to the 
control conditions.6,8 This was in contrast to the overall results of each study which demonstrated 
no significant difference between groups. The researchers theorized that those who have a known 
history of severe childhood trauma might have developed a learned reactivity to negative stimuli 
as a child that may respond more drastically to MBCT, because it is directly targeting that 
process as a means of treating their depression. Further research is warranted to investigate the 
most effective place in therapy of MBCT for patients with a known history of extensive 
childhood trauma at the time of diagnosis.  
 There are some factors that may limit the applicability of these studies to the general 
population. The first to consider is that most patients in these trials were recruited from either 
primary care or mental health clinics, and all participants were required to be in remission from 
MDD to be entered into the trials.6,7,8 This implies that the participants were patients that had 
reliable access to care and were compliant with their prior treatment plans. Additionally, the 
participants in the experimental groups completing MBCT were able to commute to and from 
sessions and commit multiple hours of their day once a week, for eight weeks to the treatment6,7,8 
This level of access and commitment may not be feasible for all those diagnosed with MDD. 
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There have been some electronic delivery methods of MBCT developed, but its effectiveness 
compared to in-person group therapy sessions is unknown.5 Finally, two of the three studies were 
conducted in the UK where all citizens have insurance coverage under the National Health 
Service. The remaining study was done in the United States, but as mentioned above, all patients 
had demonstrated remission through their prior treatment courses, implying reliable medical 
coverage. The out-of-pocket cost of MCBT for those without insurance coverage is unknown and 
not a focus of this review, but it is a factor that must be considered for implementation of this 
therapy.  
CONCLUSION 
 The results examined in this review demonstrated that mindfulness-based cognitive 
therapy was not a superior treatment of major depressive disorder when compared to other 
treatment modalities such as maintenance anti-depressant medication, active control conditions, 
and patients’ treatment as usual. The evidence garnered after calculating treatment effects was 
slightly conflicting. Two studies showed MBCT having a relatively small treatment effect 
requiring 33 and 45 people respectively, be treated with MBCT to prevent one person 
experiencing a relapse.6,7 However, one study exhibited a much larger treatment effect, only 
requiring the treatment of 15 people to prevent one relapse.8 Although the data are not 
overwhelmingly convincing, considering the millions of people worldwide affected by MDD 
each year, this review determined that MBCT is moderately effective at preventing relapse of 
depression in adults, and should not be ruled out as a treatment option.  
What remains unknown after this analysis is the exact place in therapy for MBCT. 
Further study is warranted to determine if patients with MDD would be best served using MBCT 
as an adjunct therapy, only after being stabilized on other treatment regimens as in the studies 
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examined in this review, or if it is a viable option to begin at the time of diagnosis. It is also 
warranted to investigate whether a history of trauma and abuse has any bearing on the 
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